Immunological and colorimetric determination of prostatic acid phosphatase--technical and clinical reappraisal in symptomatic patients.
We compared a selection of quantitative immunological methods for prostatic acid phosphatase (PAP) with routine colorimetric assays for total and tartrate-labile acid phosphatase and evaluated their relative clinical merits in the differential diagnosis of prostatic carcinoma. We also assessed a wide range of commercial control materials for suitability of use with these methods. Patients studied included 111 cases of prostatic carcinoma, 42 cases of benign prostatic hyperplasia, and 33 controls. The principles of the methods used included determination of enzymatic activity using p-nitrophenyl phosphate, RIA, immunoradiometric, and enzymoimmunometric assays. Performance characteristics for the immunological methods were inferior to manufacturers' precision and specificity claims. We identified control materials that were unsuitable for routine use. Poor discrimination between clinical groups was observed for all methods. Analysis by use of a receiver operator characteristic plot failed to improve this. We conclude that the immunological methods we studied offer no advantages over colorimetric methods in the differential diagnosis of prostatic cancer in symptomatic patients.
D000135:Acid Phosphatase / Q000097:blood*; D001842:Bone and Bones / Q000201:enzymology; D004796:Clinical Enzyme Tests; D003124:Colorimetry; D004912:Erythrocytes / Q000201:enzymology; D006801:Humans; D007158:Immunologic Techniques; D007527:Isoenzymes / Q000097:blood*; D008099:Liver / Q000201:enzymology; D008297:Male; D011467:Prostate / Q000201:enzymology; D011470:Prostatic Hyperplasia / Q000175:diagnosis*; D011471:Prostatic Neoplasms / Q000175:diagnosis*
D007527:Isoenzymes; D000135:Acid Phosphatase